Who Paid My Doc
Brightline-4
Research payments
$4,414,282
Through program year 2025, $4,414,282 in research payments was reported against Brightline-4, across 93 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbH & Co.KG; Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $97,048 | 31 |
| 2024 | Research | $4,317,234 | 62 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Hari Deshpande New Haven, CT Named on 9 payments
- Juneko Grilley Olson Chapel Hill, NC Named on 6 payments
- David Portnoy Germantown, TN Named on 6 payments
- Kamalesh Sankhala Beverly Hills, CA Named on 4 payments
- John Charlson Milwaukee, WI Named on 4 payments
- Sant Chawla Santa Monica, CA Named on 3 payments
- Benjamin Powers Overland Park, KS Named on 3 payments
- Abhijeet Kumar Baltimore, MD Named on 3 payments
- Andrew Pecora Hackensack, NJ Named on 3 payments
- Arun Singh Santa Monica, CA Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.